0001209191-21-039810.txt : 20210611
0001209191-21-039810.hdr.sgml : 20210611
20210611161017
ACCESSION NUMBER: 0001209191-21-039810
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210610
FILED AS OF DATE: 20210611
DATE AS OF CHANGE: 20210611
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Beaurang Pierre
CENTRAL INDEX KEY: 0001817226
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39398
FILM NUMBER: 211011371
MAIL ADDRESS:
STREET 1: C/O NURIX THERAPEUTICS, INC.
STREET 2: 1700 OWENS STREET, SUITE 205
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nurix Therapeutics, Inc.
CENTRAL INDEX KEY: 0001549595
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 270838048
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1130
BUSINESS ADDRESS:
STREET 1: 1700 OWENS STREET, SUITE 205
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: (415) 660-5320
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET, SUITE 205
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
FORMER COMPANY:
FORMER CONFORMED NAME: Nurix, Inc.
DATE OF NAME CHANGE: 20120509
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-06-10
0
0001549595
Nurix Therapeutics, Inc.
NRIX
0001817226
Beaurang Pierre
C/O NURIX THERAPEUTICS, INC.
1700 OWENS STREET, SUITE 205
SAN FRANCISCO
CA
94158
0
1
0
0
Chief Business Officer
Common Stock
2021-06-10
4
M
0
7500
1.11
A
11830
D
Common Stock
2021-06-10
4
S
0
6000
29.1469
D
5830
D
Common Stock
2021-06-10
4
S
0
1100
30.0051
D
4730
D
Common Stock
2021-06-10
4
S
0
400
30.9037
D
4330
D
Common Stock
116666
I
By Trust
Employee Stock Option (right to buy)
1.11
2021-06-10
4
M
0
7500
0.00
D
2027-02-01
Common Stock
7500
21562
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
Represents the weighted average sale price. The lowest price at which shares were sold was $28.64 and the highest price at which shares were sold was $29.62. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
Represents the weighted average sale price. The lowest price at which shares were sold was $29.67 and the highest price at which shares were sold was $30.57.
Represents the weighted average sale price. The lowest price at which shares were sold was $30.765 and the highest price at which shares were sold was $30.95.
The Reporting Person is a trustee of the Beaurang-Sligh Family Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
The option is fully vested.
/s/ Christine Ring, as Attorney-in-Fact for Pierre Beaurang
2021-06-11